Chief Executive Officer of Alfasigma, Pier Vincenzo Colli, has decided to leave the company by the end of October; at the same time, the company announces that Francesco Balestrieri will be appointed Chief Executive Officer. This change will be effective starting from 1° November 2021.
Announcing the news, the President of Alfasigma, Stefano Golinelli, commented: “I would like to express Mr. Colli all our gratitude for his continuous effort, his personal dedication and his professional passion constantly demonstrated during this long and intense period, and to wish him all the best for his future.”
Mr. Colli joined Alfa Wassermann in 2013, as General Manager, and then became CEO of Alfasigma in 2018, after the merger between Alfa Wassermann and Sigma-Tau.
“I am truly confident that Mr. Balestrieri will be able to successfully lead our ambitious development plan and growth strategies for the next years, accelerating the transformation process that Alfasigma has already started.”
Francesco Balestrieri, 52 years old, has a proven and consolidated experience across a broad range of healthcare businesses, managing roles of increasing complexity at country, regional and global level. In his career with Novartis, where he spent more than 20 years, he had the opportunity to work in different business areas from specialty Pharma, branded and standard generics drugs, to consumer OTC, while managing directly responsibilities in Europe, North America and Asia.